Analysts’ Weekly Ratings Updates for Belite Bio (BLTE)

Several brokerages have updated their recommendations and price targets on shares of Belite Bio (NASDAQ: BLTE) in the last few weeks:

• 5/26/2026 – Belite Bio had its price target lowered by Mizuho from $223.00 to $215.00. They now have an “outperform” rating on the stock.
• 5/22/2026 – Belite Bio was given a new $217.00 price target by Truist Financial Corporation.
• 5/22/2026 – Belite Bio had its “buy” rating reaffirmed by Benchmark Co..
• 5/21/2026 – Belite Bio had its “buy” rating reaffirmed by HC Wainwright. They now have a $200.00 price target on the stock.
• 4/22/2026 – Belite Bio had its “buy” rating reaffirmed by HC Wainwright. They now have a $200.00 price target on the stock.
• 4/13/2026 – Belite Bio had its “buy” rating reaffirmed by HC Wainwright. They now have a $200.00 price target on the stock.
• 4/7/2026 – Belite Bio had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/4/2026 – Belite Bio was upgraded by Wall Street Zen from “sell” to “hold”.

Insider Transactions at Belite Bio

In other Belite Bio news, insider Nathan L. Mata sold 666 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $153.21, for a total transaction of $102,037.86. Following the sale, the insider owned 440 shares of the company’s stock, valued at $67,412.40. The trade was a 60.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last quarter, insiders have sold 26,166 shares of company stock worth $4,548,351. Insiders own 13.29% of the company’s stock.

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.